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Abstract 
The human low molecular weight protein tyrosine phosphatase (LMW-PTP) has been identified as a 
target for inhibition as its overexpression leads to metastatic transformation and invasivity in several 
human cancers such as breast, colon, bladder, and kidney. Extra precision docking with Glide on LMW-
PTP isoform B was used to virtually screen 1356 compounds from the National Cancer Institute (NCI) 
diversity set II for new potential inhibitors. Twenty-one compounds identified as potential inhibitors by 
in silico screening methods were acquired from NCI.  The compounds were kinetically analyzed on LMW-
PTP isoform B to validate their selection as potential inhibitors. The best fit inhibition constants for the 
selected compounds were determined from in vitro kinetic experiments.  The results of the kinetic assay 
and inhibition constants are reported and discussed.  
Introduction 
Post-translational phosphorylation of proteins is a reversible modification that is critical for control of 
cellular functions. The phosphorylation of tyrosine residues is a ubiquitous control mechanism for 
regulation and signaling in eukaryotes. The intricate regulation of these proteins is dynamically 
controlled by phosphorylation of tyrosine side chains by protein tyrosine kinases (PTKs) and 
dephosphorylation by protein tyrosine phosphatases (PTPs). The regulated activity of PTKs and PTPs are 
vital to cell processes such as signaling, growth, migration, and gene transcription.
1 
PTPs can be divided into sub-groups including  classical pTyr specific, dual specificity, Cdc25, and low 
molecular weight phosphatases.
2
 These PTPs all share a common active site phosphate binding loop (P-
Loop) consisting of CX5R(S/T) but differ in otherwise in sequence and specificity. The low molecular 
weight PTPs have emerged as novel drug targets for their involvement in metabolic and tumor 
regulation.
1  
The human low molecular weight protein tyrosine phosphatase (LMW-PTP) exists in two active isoforms, 
A and B, and two catalytically inactive variants, isoform C and SV3 (splicing variant 3). The two active 
isoenzymes are made by alternate splicing of transcribed RNA causing isoform A to differ in a loop 
comprised of amino acid residues 40-73 that adjacent to the catalytic site,.
1,5
 The variation determines 
specificity for the isoenzymes.
1 
Human low molecular weight protein tyrosine phosphatase (LMW-PTP) is active downstream in the 
signaling pathways of growth factors and has been linked to cellular transformation.
2-5 
LMW-PTP mRNA 
and protein levels were significantly increased in human breast, colon, bladder, and kidney tumor 
samples.
6
 Overexpression of LMW-PTP in tumor cells is enough to induce neoplasticity in 
nontransformed cells.
1 
Additionally, high levels of LMW-PTP are generally prognostic of a more 
aggressive cancer.
1,8 
The oncogenic potential of LMW-PTP is closely related to an endogenous substrate, the ephrin type A2 
(EphA2) plasma membrane receptor.
1
 This EphA2 tyrosine kinase receptor  activity is strongly associated 
within human cancers, contributing to the invasivity of prostate, kidney, and lung cancers. The ligand-
independent stimulation of EphA2 increases cellular migration and progression of tumors.
7 
The 
overexpression of EphA2 is associated with increased expression of LMW-PTP which also regulates its 
activity through dephosphorylation.
1
 When associated with EphA2, LMW-PTP is less available for 
dephosphorylate p190Rho-Gap, which leads to weakened cell-matrix adhesion. This reduced activity on 
the p190Rho-Gap leads to weakened cell-matrix adhesion.
6 
The Rho GTPases are instrumental in the 
regulation of cytoskeletal reorganization driving translocation.
7 
It has been demonstrated that diverse molecules modulate the activity of LMW-PTP, including 
flavonoids, quercetin and morin, adenine, and purines.
9-12
 Attempts to synthesize inhibitors of LMW-PTP 
have been impeded by insufficient data about the inhibitor – protein interactions.
13 
Although a known 
inhibitor of LMW-PTP, pyridoxal 5’-phosphate (PLP) displays the tight binding (Kis = 7.6 µM, pH 5)  
necessary for  good inhibition,  it is also a necessary cofactor for other enzymes, and thus lacks the 
specificity required.
14
 Two inhibitors for bovine-LMW-PTP (which has 94% sequence homology with the 
human enzyme), ptp-043 and ptp-194, have similar  Kis values ( 11 ± 2 µM and 9 ± 3 µM respectively).
15
 
These compounds were discovered through virtual screening of the Chem Div collection (version 2004) 
via Autodock 3.0.
15
 The search for novel inhibitors of LMW-PTP has been aided by virtual screening of 
compound libraries.
8,15,16   
To increase the speed of discovery, the publicly available National Cancer Institute’s (NCI) Diversity Set II 
was virtually screened in silico using  Glide.
8
 Those compounds which showed the highest in silico 
binding affinity were obtained from the NCI/DTP Open Chemical Repository, and tested for inhibitory 
activity in vitro with LMW-PTP isoform B. The most promising target compounds will be used as scaffolds 
for optimizing inhibition. 
Results and Discussion 
The in silico screening of the National Cancer Institute’s Diversity Set II led to the selection of 24 
compounds for in vitro analysis. Given the small amount of sample (5 mg), initial analysis of inhibition 
was conducted at a single final inhibitor concentration (450 µM) (single point assay, see supplemental 
materials)  Promising candidates were then tested in either  a multiple-point micro or macro assay, 
depending on the amount of inhibitor available.  For solubility reasons, two compounds (639174 and 
62840) were tested at a lower single concentration  but showed little inhibition in micro assays ( Ki  =538 
µM and 3.30 mM, respectively). Nine compounds (107022, 76988, 182400, 156563, 38042, 82560, 
77468, 19803, and 7578) showed inhibition constants less than 450 µM at pH 5.5. These were purchased 
from Sigma-Aldrich and were then tested further.  The results of single point test, micro and macro 
assays are summarized in table 1.  
Five of the inhibitors (107022, 76988, 182400, 156563, and 38042) showed strong inhibition, with (Ki 
values less than 100 µM.. The structures of these inhibitors are shown in Figure 1. Compounds 107022 
(Kis 10.8 ± 1.0 µM) and 76988 had and (18.8 ± 2.1 µM) had inhibition constants similar to that of PLP (Kis 
=7.6 ± 1.8 µM). These compounds interacted with the P-loop through highly oxygenated ring systems 
(figures 2 and 3 respectively). Two compounds (156563 and 38042), interacted with the P-loop through 
an anionic carboxylate (figures 4 and 5).  A third compound with the anionic carboxylate is predicted to 
place the functional group distal to the active site, and direct chlorine atoms toward it instead (figure 6). 
Two of these (182400 and 38042) gave better fits to the kinetic data as mixed inhibitors. It should be 
noted that although some of our most effective inhibitors best fit competitive inhibition, others gave 
best fits to noncompetitive inhibition (182400 and 38042) and uncompetitive inhibtion (77468). The 
structure of compound 77468 docked into the active site is shown in figure 7 for comparison. The pose 
in figure 7 shows that is possible for 77468 to bind to the protein while inorganic phosphate is still 
covalently attached to the active site cysteine and effect inhibition by reducing the rate that phosphate 
is cleaved by water. Inhibition models other than competitive (as displayed by 182400 and 38042) might 
arise from different modes of binding of these inhibitors with LMW-PTP.  
All of the top five inhibitors have rings which bind in the active site. The top two compounds, 107022 
and 76988, are shown to use their highly hydroxylated rings to interact with Arg 18 in the P-loop and  a 
proximal Asn 50. The structure of 156563 shares similarity with NSC 45576 (Figure 1), which was 
included in Diversity Set I and had an IC50 of 3.9 µM at pH 5. These two compounds exhibit similarities in 
the constraint of the double bonded nitrogen and the oxygenated fused ring system in the active site. A 
key difference between the two molecules is the type of interaction with the protein. 45576 uses a 
sulfonate, while 156563 utilizes a carboxylic acid. The structure of 76988 resembles the flavonoids, 
quercetin and morin, previously reported to activate and inhibit LMW-PTP respectively.  
Conclusion 
The in silico screening of the NCI Diversity Set II was conducted with Glide for LMW-PTP isoform B. The 
potential inhibitors from the in silico screening were analyzed by in vitro kinetic assays.  Nine of 24 
(37.5%) selected screened inhibitors displayed  Ki less than 450 µM, while five (20.8%) had Ki less than 
100 µM. The compounds 107022 and 76988 have Ki values similar to that of PLP, a nonspecific cellular 
inhibitor and as such might prove to be useful candidates for further investigation. The screening of 
diversity set II has produced new scaffolds for optimization.   Additional testing to gauge the specificity 
of these new candidates for LMW-PTP would be useful. 
Although the screening of Diversity Set II identified inhibitors for LMW-PTP with Ki less than 100 µM, the 
screen also produced compounds which had Ki in the millimolar range. The origin of the wide range of 
results is unclear but indicates that more information about small molecule interactions with LMW-PTP 
is needed. 
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 Table1: Experimentally determined inhibition constants of compounds for isoform B.  
Compound (NSC#) Competitive Uncompetitive Mixed 
 Kis (µM) Kii (µM) Ki (µM) 
107022 10.8 ± 1.0   
76988 18.8 ± 2.1   
182400*   26.0 ± 8.0 
35.0 ± 6.7 
156563 33.5 ± 8.2   
38042*   73.2 ± 29.2 
108.2 ± 30.3 
82560 128.0 ± 29.9   
77468**  121.1 ± 9.9  
19803 125.7 ± 23.1   
7578 161 ± 19   
140899 493   
639174 538   
91529 635   
114436 730   
50572 925   
403379 1.185x10
3 
  
81750 1.563x10
3
   
362639 1.65x10
3
   
146554 2.23x10
3
   
58-85-5
# 
2.33x10
3
 ± 0.33x10
3 
  
134580 2.78x10
3
   
62840 3.30x10
3
   
4649-09-6
# 
7.19x10
3 
± 0.66x10
3 
  
205842 17.65x10
3 
  
89720 66.5x10
3 
± 39.3x10
3
   
*Best fit noncompetitive inhibition 
**Best fit uncompetitive inhibition 
#
 CAS number, as no NSC number available 
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Figure 1. A. Structures of inhibitors having Ki less than 100 µM. B. Uncompetitive inhibitor 77468. C. 
Compound 45576, a previously reported inhibitor of LMW-PTP isoform B. 
 
 
Figure 2. The best fit orientation of 107022 in the active site of 1XWW as predicted by Glide. Also shown 
are the interactions with active site residues.  
 Figure 3. The best fit orientation of 76988 in the active site of 1XWW as predicted by Glide. Also shown 
are the interactions with active site residues. 
 
Figure 4. The best fit orientation of 156563 in the active site of 1XWW as predicted by Glide. Also shown 
are the interactions with active site residues. 
 
 Figure 5. The best fit orientation of 38042 in the active site of 1XWW as predicted by Glide. The best fit 
was mixed inhibition. Also shown are the interactions with active site residues. 
 
 
Figure 6. The best fit orientation of 182400 in the active site of 1XWW as predicted by Glide. The best fit 
was mixed inhibition. Also shown are the interactions with active site residues. 
 Figure 7. The best fit orientation of 77468 in the active site of 1XWW as predicted by Glide. The best fit 
was uncompetitive. Also shown are the interactions with active site residues. 
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Supplemental Materials 
Experimental 
Materials 
Compounds with NSC numbers 38042, 205842, 639174, 50572, 114436, 146554, 182400, 140899, 
76988, 134580, 81750, 156563, 62840, 82560, 77468, 7578, 91529, 107022, 403379, 19803, 362639 
were obtained from the National Cancer Institute Developmental Therapeutics Program. P-nitrophenyl 
phosphate was purchased from Research Organics. Compounds: 58-85-5, 4649-09-6, and 89720, as well 
as all chemicals for solutions and preparation were purchased from Sigma-Aldrich unless otherwise 
noted. All absorbance readings were read on a SpectraMax 340PC plate reader. 
In silico screening parameters 
The in silico screen for potential inhibitors was conducted using the National Cancer Institute’s (NCI) 
Diversity Set II (http://dtp.nci.nih.gov/). Using Maestro from Schrödinger, the protein crystal structure 
(1XWW) was imported from the Protein Data Bank and prepared using the Protein Preparation Wizard. 
The deletion of waters beyond section is set to 0 and the protein reprocessed. Then the cocrystallized 
glycerol and sulfate were removed and the pH range was set to 5.5 ± 2. The protein was refined with 
exhaustive sampling and optimized. After optimization and deselecting the Hydrogens only option, the 
protein was minimized. Using Glide, a receptor grid was generated that was centered on the active site 
cysteine (Cys 12). The ligands were prepared using LigPrep with the force field MMFFs (a pH range of 5.5 
± 2), Epik scores, and set to generate at most four per ligand. The docking was done using Glide, with the 
receptor grid and prepared ligands. Epik state penalties were added, the screen was set to write out at 
most 10 poses per ligand, and write out residue interaction scores for residues within 20 angstroms. 
Ligands of interest were chosen based on the most negative docking scores and were then ordered from 
NCI. 
Preparation of LMW-PTP isoform B 
LMW-PTP isoform B (PDB code: 1XWW) was made in E. Coli after transformation of competent cells with 
a plasmid (provided by David Bernlohr, University of Minnesota) containing human PTP in fusion with 
glutathione S-transferase under the control of the lac promoter as described.
18
 Fusion protein 
expression was initiated with IPTG. The fusion protein was used for all kinetic assays; stock solution was 
diluted two-fold in glycerol and stored as a liquid stock at -20°C. 
Preparation of Solutions 
A 1.0 M sodium acetate/acetic acid pH 5.5 buffer was prepared by dissolving 27.2 g sodium acetate in 
200 mL of E-pure H2O; 30 mL of 1.0 M acetic acid (5.7 mL glacial acetic acid/100 mL) was added and the 
pH adjusted accordingly. P-nitrophenyl phosphate (pnpp) solution (50.0 mM), was prepared by adding 
0.928 g to 50 mL H2O.  This stock solution was diluted to make substock solutions for enzyme assays of 
10.0 mM, 5.0 mM, 2.5 mM, 1.25 mM, 0.800 mM, 0.625 mM, 0.500 mM, 0.374 mM, and 0.300 mM. 
Potassium hydroxide solution, 0.5 M, was prepared using 14.03 g KOH in 500 mL of H2O. Pyridoxal 5’-
phosphate (PLP) solution, 0.263 mM, was prepared by dissolving 6.5 mg in 100 mL H2O and diluted 1/10 
and 1/20 to 26.3 µM and 13.15 µM respectively. PLP and substrate solutions were stored in -20°C 
freezer. Inhibitors utilized in the micro assay were dissolved in DMSO to create solutions that had an 
approximate initial concentration of 18 mM.  
Enzyme Assay 
Enzyme assays used to determine kinetic parameters were conducted by adding specified amounts of a 
stock 1.0 M sodium acetate/acetic acid buffer solution, H2O, and p-nitrophenyl phosphate (pnpp)at final 
concentrations in the assay mixture of 2.0 mM, 1.0 mM, 0.5 mM, 0.25 mM, 0.16 mM, 0.125 mM, 0.10 
mM, 0.075 mM, and 0.06 mM) to microcentrifuge tubes. Enzyme was added at time intervals to initiate 
the reaction. After fifteen minutes, aliquots were removed to a 96-well plate containing KOH (0.5 M, 200 
µL) to quench the reaction. A405 values were corrected for absorbance at each substrate concentration 
in the absence of enzyme. 
 The appropriate enzyme dilution was determined in advance by making serial dilutions of the enzyme 
(glycerol stock stored at -20
0
C) and using the dilution which gave under specified test conditions an A405 
of 0.120 in the plate reader. This dilution, used in all further assays, gave linear changes in concentration 
of product over the time course chosen for inhibition studies, ensuring that quenched single point 
absorbance values reflected the initial rates. Initial velocities were also directly proportional to enzyme 
concentration, indicating the validity of the enzyme assay.  
Validation of the enzyme assay was also conducted using PLP as a known inhibitor.  PLP in our assays 
was determined to be a competitive inhibitor with a Kis of 3.73 ± 0.39 µM, in accord with published 
values. Enzyme assays 2.5% DMSO did not affect the assay results, showing that DMSO used to dissolve 
the inhibitors had no effect on the enzyme assay.  The activity of the glycerol enzyme stock was 
measured daily as a quality control measure.  Activity varied minimally and randomly over a several 
month period.   
Scaled Enzyme Assays: 
Given the small amount of sample received from NCI, several different sets of assay conditions were 
used to determine if the samples inhibited the enzyme (single point assay) and then to model the 
inhibition and determine kinetic parameters (macro and micro assays).   These include single point, 
macro, and mini assays.  
For the single point assay (conducted at one substrate concentration), duplicate reactions (Vfinal = 100 
µL) containing inhibitor (18 – 0.36 mM, 2.5 µL), H2O (62.5 µL), acetic acid/acetate buffer solution (1.0 M, 
5 µL), and pnpp (1.25 mM, 20 µL) were performed. At 30 second intervals, enzyme (10 µL) diluted in 1.0 
M acetic acid/acetate buffer solution was added and allowed to react for 15 minutes. The reaction was 
quenched by adding KOH (0.5 M, 150 µL) to the reaction mixture and 240 µL of the quenched reaction 
mixtures were added to a 96-well plate for analysis. 
The macro assay was used for compounds purchased from Sigma. The reactions mixtures (Vfinal = 500 µL) 
contained acetic acid/acetate buffer solution (1.0 M, 50 µL), H2O (330 µL) , varying concentrations of 
pnpp ( 100 µL) in the absence of inhibitor (330 µL  water) and presence of two different fixed 
concentrations of inhibitor (0.5 mM to 10.0 mM, 330 µL) whose concentrations were determined by the 
single point assay.  Measurements in the presence and absence of inhibitors were done in the same 
assay. At 30 second intervals, enzyme (20 µl) was added to the reaction mixture which was allowed to 
react for 15 minutes. The reaction was quenched by removing 100 µL of the reaction mixture to a 96-
well plate containing 150 µL of 0.5 M KOH.  
The micro assay was used for compounds received from NCI after the single point test. The reaction 
mixture (Vfinal = 100 µL) contained acetic acid/acetate buffer (1.0 M, 5 µL), H2O (62.5 µL), varying 
concentrations of pnpp, and inhibitor (18.0 to 0.36mM, 2.5µL). Inhibition analysis was conducted 
simultaneously with two different concentrations of inhibitor based on calculations from the single point 
test. Measurements in the presence and absence of inhibitors were done in the same assay. At 30 
second intervals, enzyme (10 µl) was added to the reaction mixture which was allowed to react for 15 
minutes. The reaction was quenched by removing 100 µL of the reaction mixture to a 96-well plate 
containing 150 µL of 0.5 M KOH.  
Analysis using Visual Enzymics© 
The inhibition constants (Kix) were calculated using Visual Enzymics through the IgorPro interface using 
the one substrate one inhibitor section of the program. In the data page, the concentration (mM) of the 
substrates and inhibitor in the reaction mixture were entered along with the velocity of the reaction. 
The standard deviation and mask were set to 1. A405 values were converted to molarity units using an 
extinction coefficient and path length for the plate. The data was fit to the equations for competitive, 
uncompetitive, and mixed inhibition models.  
 
